glutathione nac alpha lipoic acid N-Acetyl-L-Cysteine & R-Alpha-Lipoic 500 mg/200 mg N-acetyl-L-cysteine (NAC) and alpha-lipoic acid (ALA) are highly complementary nutrients. Together, they support the clearing of normal cellular debris and maintain normal cellular function.* ProCaps Laboratories | ALA +

In addition, lower levels of Vitamin B12 in the blood may also be associated with a reduced bone mass or propensity to develop osteoporosis

Approval Timeline and Availability CagriSema: Ahead in the Race FDA Submission: December 18, 2025 (NDA filed) Expected FDA Decision: Q4 2026 or Q1 2027 Predicted Launch: Mid-2027 Advantage: 6-12 month head start on retatrutide REDEFINE Program Status: REDEFINE-1: Completed (obesity, 20.4% weight loss) REDEFINE-2: Completed (type 2 diabetes, 13.7% weight loss) REDEFINE-3: Ongoing (cardiovascular outcomes trial) REDEFINE-8: Ongoing (body composition study) High-dose CagriSema (2.4/7.2mg): Starting late 2026 Retatrutide: More Trials Needed FDA Submission: Expected Q4 2026 or Q1 2027 Expected FDA Decision: Late 2027 Predicted Launch: Q1-Q2 2028 TRIUMPH Program Status: TRIUMPH-4: Completed (osteoarthritis, 28.7% weight loss) TRIUMPH-1: Complete 28.3% weight loss (May 2026) TRIUMPH-2: Expected Q3Q4 2026 (obesity + type 2 diabetes) TRIUMPH-3: Expected later 2026 (obesity + cardiovascular disease) TRIUMPH-6: Weight maintenance trial (ongoing) Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema

10.1111/apa.12735 Acta Paediatr

149 Quintana-CabreraR.Fernandez-FernandezS.Bobo-JimenezV.EscobarJ.SastreJ.AlmeidaA.et al (2012)

The Physical and Mental Benefits of Back Massage Relief from Chronic Muscle Tension and Pain Tight muscles develop from poor posture, repetitive movements, and stress